Reading the records
Peptide Therapy News links to the records behind its reports. This page collects them, with a note on what each explains. The links open the original page or PDF, so you can check the details in context.
The publication’s source-review cutoff is 27 October 2026. Dates below identify the announcement, document or source update. An old announcement can explain a past decision without answering what happened later.
The source desk
Step 3: Clinical Research
Explains what phase 2 testing can tell researchers, and why more testing follows.
National supply and the rules for compounded copies
Tracks the shortage decisions and grace periods for compounded copies, medicines prepared outside approved finished-product manufacturing.
FDA’s two-table account of peptide nominations
Shows Category 2 and withdrawn requests in separate tables. Withdrawal does not mean safety clearance.
FDA’s safety concerns about unapproved medicines
Explains why compounded medicines are not FDA-approved and why retatrutide cannot be compounded under federal law.
American Diabetes Association highlights retatrutide phase 2 findings
Announces two mid-stage retatrutide studies: one in adults with type 2 diabetes, one in adults without it.
Retatrutide obesity trial: the original paper
Reports weight loss and side effects, including stomach problems and a faster heartbeat, in adults without type 2 diabetes.
Retatrutide diabetes trial: the original paper
Reports blood-sugar and weight findings in adults with type 2 diabetes. This was a different study from the obesity trial.
The March 2024 semaglutide cardiovascular decision
Sets out the heart-risk approval for semaglutide, sold as Wegovy, and the adults it covers.
Wegovy (semaglutide) prescribing information
Gives semaglutide’s warnings and the trial evidence behind the heart-risk approval.
Drug reverses signs of liver disease in people living with HIV
Announces the year-long tesamorelin study that found lower liver fat in adults living with HIV.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV
Reports the liver-fat findings in adults with HIV and fatty liver disease.
Original Egrifta (tesamorelin) approval letter
Records tesamorelin’s original approval for excess abdominal fat in HIV-associated lipodystrophy, a change in body-fat distribution.
Egrifta WR (tesamorelin) supplement approval letter
Approves a new tesamorelin formulation and multiple-dose presentation. It is not a general weight-loss approval.
Egrifta WR (tesamorelin) prescribing information
Specifies adults, rules out a general weight-loss use, and explains warnings about blood sugar, fluid retention and raised growth-factor levels.